Data from Phase III study OASIS 3 support efficacy and long-term safety of investigational compound elinzanetant in the treatment of moderate to severe vasomotor symptoms associated with menopause

BERLIN–(BUSINESS WIRE)–Bayer will present detailed results from the Phase III study OASIS 3, providing supporting efficacy data and sustained safety data over 52 weeks for the investigational compound elinzanetant, adding to the positive results of the OASIS 1 and 2 studies. These data will be presented at the 2024 annual meeting of The Menopause Society (TMS) taking place from September 10-14, in Chicago, IL, USA. OASIS 3 is a Phase III efficacy and long-term safety study of elinzanetant for